Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
2.910
-0.010 (-0.34%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Can-Fite BioPharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 5.53 | 4.83 | 4.28 | 2.98 | 4.39 | Upgrade
|
| Short-Term Investments | 3.01 | 3.06 | 4.64 | 5 | 14.51 | Upgrade
|
| Trading Asset Securities | - | - | - | 0.01 | 0.24 | Upgrade
|
| Cash & Short-Term Investments | 8.54 | 7.89 | 8.92 | 7.99 | 19.14 | Upgrade
|
| Cash Growth | 8.28% | -11.60% | 11.71% | -58.27% | 129.40% | Upgrade
|
| Prepaid Expenses | 0.83 | 1.02 | 0.91 | 1.12 | 0.88 | Upgrade
|
| Other Current Assets | 0.07 | 0.08 | 0.08 | 0.05 | 0.05 | Upgrade
|
| Total Current Assets | 9.44 | 8.98 | 9.91 | 9.16 | 20.07 | Upgrade
|
| Property, Plant & Equipment | 0.07 | 0.14 | 0.08 | 0.13 | 0.19 | Upgrade
|
| Total Assets | 9.51 | 9.12 | 9.99 | 9.28 | 20.25 | Upgrade
|
| Accounts Payable | 1.16 | 0.62 | 0.43 | 0.9 | 0.95 | Upgrade
|
| Accrued Expenses | 1.11 | 0.98 | 0.94 | 0.78 | 0.91 | Upgrade
|
| Current Portion of Leases | 0.06 | 0.05 | 0.03 | 0.05 | 0.05 | Upgrade
|
| Current Unearned Revenue | 0.41 | 0.41 | 0.62 | 0.78 | 0.82 | Upgrade
|
| Total Current Liabilities | 2.73 | 2.05 | 2.02 | 2.5 | 2.73 | Upgrade
|
| Long-Term Leases | 0.02 | 0.05 | 0.01 | 0.01 | 0.07 | Upgrade
|
| Long-Term Unearned Revenue | 1.18 | 1.58 | 1.71 | 2.3 | 3.07 | Upgrade
|
| Total Liabilities | 3.92 | 3.68 | 3.75 | 4.81 | 5.87 | Upgrade
|
| Additional Paid-In Capital | 180.65 | 170.67 | 163.6 | 154.19 | 153.93 | Upgrade
|
| Retained Earnings | -176.19 | -166.36 | -158.48 | -150.85 | -140.67 | Upgrade
|
| Comprehensive Income & Other | 1.13 | 1.13 | 1.13 | 1.13 | 1.13 | Upgrade
|
| Total Common Equity | 5.59 | 5.44 | 6.24 | 4.47 | 14.38 | Upgrade
|
| Shareholders' Equity | 5.59 | 5.44 | 6.24 | 4.47 | 14.38 | Upgrade
|
| Total Liabilities & Equity | 9.51 | 9.12 | 9.99 | 9.28 | 20.25 | Upgrade
|
| Total Debt | 0.07 | 0.1 | 0.04 | 0.06 | 0.12 | Upgrade
|
| Net Cash (Debt) | 8.47 | 7.78 | 8.88 | 7.93 | 19.02 | Upgrade
|
| Net Cash Growth | 8.81% | -12.37% | 12.08% | -58.32% | 129.76% | Upgrade
|
| Net Cash Per Share | 5.14 | 10.73 | 20.84 | 29.15 | 103.14 | Upgrade
|
| Filing Date Shares Outstanding | 4.29 | 1.04 | 0.5 | 0.41 | 0.27 | Upgrade
|
| Total Common Shares Outstanding | 2.62 | 0.99 | 0.45 | 0.27 | 0.27 | Upgrade
|
| Working Capital | 6.71 | 6.93 | 7.89 | 6.66 | 17.34 | Upgrade
|
| Book Value Per Share | 2.14 | 5.47 | 13.77 | 16.45 | 52.89 | Upgrade
|
| Tangible Book Value | 5.59 | 5.44 | 6.24 | 4.47 | 14.38 | Upgrade
|
| Tangible Book Value Per Share | 2.14 | 5.47 | 13.77 | 16.45 | 52.89 | Upgrade
|
| Machinery | 0.02 | 0.08 | 0.28 | 0.28 | 0.27 | Upgrade
|
| Leasehold Improvements | - | - | 0.01 | 0.01 | 0.01 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.